Jinyuan Ho

Assistant Professor of Practice

Calculated based on number of publications stored in Pure and citations from Scopus

Research activity per year

Personal profile

Personal profile

Dr. Ho joined the Wisdom Lake Academy of Pharmacy, XJTLU in April 2024 as an Assistant Professor of Practice. He studied chemical biology and molecular biophysics at Academia Sinica and then graduated from Taiwan University. After three years of postdoctoral training in antiviral research, he moved to Beijing, decided to transition his focus towards the CAR-T cell therapy. 

Dr. Ho has served as R&D director and Senior R&D Director in Senlang-Taihe biotechnology companies, with one IND approval. At Neukio, as the Principal Scientist, he focused on the development of functional components for editing iPSC derived CAR-NK cells, a pivotal approach  of the off-the-shelf immunotherapies before joining XJTLU.

His lab is interested on enhancing the migration and the invasion of immune cells into tumor microenvironment. Moreover, he is also interested in developing nanobodies that can specifically target intracellular neoantigens. Students who are interested in cell therapy are welcome to join us !

Ho, Jinyuan  — Scopus


何晋元博士于2024年4月加入西交利物浦大学慧湖药学院,任实践助理教授。本科与研究生阶段就读于台湾阳明交通大学, 主要通过二维电泳与质谱仪鉴定受药物影响的蛋白分子。而后在台湾中央研究院加入国际研究生学程,学习化学生物学和分子生物物理学,主要研究脢类蛋白催化的化学机制,2011年取得台湾大学博士学位。在长庚大学进行了三年的天然物对肠病毒71型与甲型流感的抗病毒研究后,他到了北京并将研究重点转移到CAR-T细胞治疗上。

他曾担任河北森朗以及河北森朗泰禾生物技术公司的研发总监和高级研发总监,所主导的研发项目Senl_B19, 成功获得了IND批准。在加入西交利物浦大学之前,何博士在上海星奕昂任首席科学家,专注于开发用于编辑iPSC衍生CAR-NK细胞的功能组件。实验室对于通过基因或小分子提升免疫细胞功能以及利用病毒、细菌、和各类免疫细胞进行肿瘤联合治疗的研发与应用均有兴趣。欢迎对细胞治疗感兴趣的同学加入!


Research interests

  • Viral and non-viral gene editing  
  • Nanobody screening for tumor-related protein targets
  • Cell therapies, including CAR-T and TILs


  • 基于病毒与非病毒载体的基因递送
  • 靶向肿瘤相关抗原的纳米抗体筛选
  • 细胞治疗


2024.04- present: Assistant Professor of Practice, XJTLU, Suzhou, China

2022.06-2024.03: Principal Scientist of R&D, Neukio Biotherapeutics, Shanghai, China

2020.07-2022.05: R&D Senior Director, Hebei Senlang-Taihe, Shijiazhuang, China

2018.06-2020.06: R&D Director, Hebei Senlang Biotechnology, Shijiazhuang, China

2016.04-2018.05: Assistant President, Geno-immune Medical Institute, Shenzhen, China

2015.04-2016.03: R&D Manager, Beijing America Yuva, Beijing, China

2012.07-2015.03: Postdoctoral Researcher, Chang-Gung University, Taiwan, China


APH423, Pinciples of Toxicology (module leader)

Expertise related to UN Sustainable Development Goals

In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):

  • SDG 3 - Good Health and Well-being

Related documents

Education/Academic qualification

PhD, TIGP, Taiwan University

Sept 2006Jun 2011

Master, Biochemistry, National Yang Ming Chiao Tung University

Sept 2001Jun 2003

Bachelor, Life Science, National Yang Ming Chiao Tung University

Sept 1997Jun 2001


  • RM Therapeutics. Pharmacology
  • Cell Therapies
  • Chimeric Antigen Receptor
  • Nanobodies
  • Acute Myeloid Leukemia (AML)
  • Q Science (General)

Person Types

  • Staff


Dive into the research topics where Jinyuan Ho is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

Collaborations and top research areas from the last five years

Recent external collaboration on country/territory level. Dive into details by clicking on the dots or